Catalyst Biosciences Announces Proposed Public Offering of Common Stock

Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced that it is offering, subject to market conditions, shares of its common stock in an underwritten public offering.

As quoted in the press release:

The Company anticipates using the net proceeds from this offering for general corporate purposes, which may include clinical and manufacturing activities for CB 2679d and Marzeptacog alfa (activated), research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. All of the shares in the offering are to be sold by the Company.

Click here to read the full press release.